NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma

This study has been terminated.
(Low recruitment due to change in standard of care)
Sponsor:
Collaborator:
Institute of Cancer Research, United Kingdom
Information provided by (Responsible Party):
Ludwig Institute for Cancer Research
ClinicalTrials.gov Identifier:
NCT01810016
First received: March 8, 2013
Last updated: June 16, 2016
Last verified: June 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: December 2016
  Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)